Skip to main content
NCBI home page
Gut logoLink to Gut
. 2001 Jun;48(6):843–848. doi: 10.1136/gut.48.6.843

Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis

A Gramenzi 1, P Andreone 1, S Fiorino 1, C Camma 1, M Giunta 1, D Magalotti 1, C Cursaro 1, C Calabrese 1, V Arienti 1, C Rossi 1, F Di 1, M Zoli 1, A Craxi 1, G Gasbarrini 1, M Bernardi 1
PMCID: PMC1728334  PMID: 11358906

Abstract

BACKGROUND—The role of interferon treatment on the natural history of hepatitis C virus related cirrhosis is under debate.
AIM—To evaluate the effect of interferon on the clinical course of compensated hepatitis C virus related cirrhosis.
PATIENTS AND METHODS—Seventy two cirrhotic patients treated with interferon and 72 untreated controls matched treated patients with for quinquennia of age, sex, and Child-Pugh's score were enrolled in a prospective non-randomised controlled trial. Treated patients received leucocytic interferon alfa, with an escalating schedule for 12 months. The incidence and risk (Cox regression analysis) of clinical complications (hepatocellular carcinoma, ascites, jaundice, variceal bleeding, and encephalopathy) and death were calculated.
RESULTS—Over median follow up periods of 55 months for treated and 58 for untreated subjects, seven and nine patients, respectively, died, and 20 and 32, respectively, developed at least one clinical complication (ns). Hepatocellular carcinoma developed in six treated and 19 untreated patients (p=0.018). Seven treated patients showed sustained aminotranferase normalisation and none died or developed complications. Clinical complications were significantly associated with low albumin, bilirubin, and prothrombin activity while hepatocellular carcinoma was significantly related to no treatment with interferon, oesophageal varices, and high α fetoprotein levels. By stratified analysis, the beneficial effect of interferon was statistically evident only in patients with baseline α fetoprotein levels ⩾20 ng/ml.
CONCLUSIONS—Interferon does not seem to affect overall or event free survival of patients with hepatitis C virus related cirrhosis while it seems to prevent the development of hepatocellular carcinoma. Patients who achieved sustained aminotransferase normalisation survived and did not develop any complications during follow up.


Keywords: hepatocellular carcinoma; cirrhosis; hepatitis C virus; interferon alfa

Full Text

The Full Text of this article is available as a PDF (176.1 KB).

Figure 1  .

Figure 1  

Open in a new tab

(A) Cumulative probability of overall survival and (B) event free survival in treated and untreated patients. Number of patients at risk are shown in parentheses.

Figure 2  .

Figure 2  

Open in a new tab

(A) Cumulative probability of hepatocellular carcinoma (HCC) among treated and untreated patients. (B) Cumulative probability of HCC among treated and untreated patients according to baseline α fetoprotein (AFP) serum levels (treated AFP <20 ng/ml v untreated <20 ng/ml, ns; treated AFP ⩾20 ng/ml v untreated AFP ⩾20 ng/ml, p=0.0026). Number of patients at risk are shown in parentheses.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andreone P., Cursaro C., Gramenzi A., Trevisani F., Gasbarrini G., Bernardi M. Interferon and hepatocellular carcinoma. Lancet. 1996 Jan 20;347(8995):195–195. [PubMed] [Google Scholar]
  2. Baffis V., Shrier I., Sherker A. H., Szilagyi A. Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection. Ann Intern Med. 1999 Nov 2;131(9):696–701. doi: 10.7326/0003-4819-131-9-199911020-00011. [DOI] [PubMed] [Google Scholar]
  3. Bellentani S., Tiribelli C., Saccoccio G., Sodde M., Fratti N., De Martin C., Cristianini G. Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study. Hepatology. 1994 Dec;20(6):1442–1449. doi: 10.1002/hep.1840200611. [DOI] [PubMed] [Google Scholar]
  4. Benvegnù L., Chemello L., Noventa F., Fattovich G., Pontisso P., Alberti A. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer. 1998 Sep 1;83(5):901–909. doi: 10.1002/(sici)1097-0142(19980901)83:5<901::aid-cncr15>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  5. Beppu K., Inokuchi K., Koyanagi N., Nakayama S., Sakata H., Kitano S., Kobayashi M. Prediction of variceal hemorrhage by esophageal endoscopy. Gastrointest Endosc. 1981 Nov;27(4):213–218. doi: 10.1016/s0016-5107(81)73224-3. [DOI] [PubMed] [Google Scholar]
  6. Bruno S., Silini E., Crosignani A., Borzio F., Leandro G., Bono F., Asti M., Rossi S., Larghi A., Cerino A. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology. 1997 Mar;25(3):754–758. doi: 10.1002/hep.510250344. [DOI] [PubMed] [Google Scholar]
  7. Cammà C., Di Marco V., Lo Iacono O., Almasio P., Giunta M., Fuschi P., Vaccaro A., Fabiano C., Magrin S., Di Stefano R. Long-term course of interferon-treated chronic hepatitis C. J Hepatol. 1998 Apr;28(4):531–537. doi: 10.1016/s0168-8278(98)80274-2. [DOI] [PubMed] [Google Scholar]
  8. Chiaramonte M., Stroffolini T., Caporaso N., Coppola R., Craxì A., Gaeta G. B., Sagnelli E., Zanetti A. R. Hepatitis-C virus infection in Italy: a multicentric sero-epidemiological study (a report from the HCV study group of the Italian Association for the Study of the Liver). Ital J Gastroenterol. 1991 Dec;23(9):555–558. [PubMed] [Google Scholar]
  9. Fattovich G., Giustina G., Degos F., Diodati G., Tremolada F., Nevens F., Almasio P., Solinas A., Brouwer J. T., Thomas H. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol. 1997 Jul;27(1):201–205. doi: 10.1016/s0168-8278(97)80302-9. [DOI] [PubMed] [Google Scholar]
  10. Fattovich G., Giustina G., Degos F., Tremolada F., Diodati G., Almasio P., Nevens F., Solinas A., Mura D., Brouwer J. T. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997 Feb;112(2):463–472. doi: 10.1053/gast.1997.v112.pm9024300. [DOI] [PubMed] [Google Scholar]
  11. Idilman R., De Maria N., Colantoni A., Dokmeci A., Van Thiel D. H. Interferon treatment of cirrhotic patients with chronic hepatitis C. J Viral Hepat. 1997 Mar;4(2):81–91. doi: 10.1111/j.1365-2893.1997.tb00209.x. [DOI] [PubMed] [Google Scholar]
  12. Imai Y., Kawata S., Tamura S., Yabuuchi I., Noda S., Inada M., Maeda Y., Shirai Y., Fukuzaki T., Kaji I. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med. 1998 Jul 15;129(2):94–99. doi: 10.7326/0003-4819-129-2-199807150-00005. [DOI] [PubMed] [Google Scholar]
  13. Koretz R. L. Interferon and hepatocellular carcinoma. Lancet. 1996 Jan 20;347(8995):194–195. doi: 10.1016/s0140-6736(96)90379-7. [DOI] [PubMed] [Google Scholar]
  14. Mazzella G., Accogli E., Sottili S., Festi D., Orsini M., Salzetta A., Novelli V., Cipolla A., Fabbri C., Pezzoli A. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol. 1996 Feb;24(2):141–147. doi: 10.1016/s0168-8278(96)80022-5. [DOI] [PubMed] [Google Scholar]
  15. Niederau C., Lange S., Heintges T., Erhardt A., Buschkamp M., Hürter D., Nawrocki M., Kruska L., Hensel F., Petry W. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology. 1998 Dec;28(6):1687–1695. doi: 10.1002/hep.510280632. [DOI] [PubMed] [Google Scholar]
  16. Nishiguchi S., Kuroki T., Nakatani S., Morimoto H., Takeda T., Nakajima S., Shiomi S., Seki S., Kobayashi K., Otani S. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995 Oct 21;346(8982):1051–1055. doi: 10.1016/s0140-6736(95)91739-x. [DOI] [PubMed] [Google Scholar]
  17. Oka H., Tamori A., Kuroki T., Kobayashi K., Yamamoto S. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology. 1994 Jan;19(1):61–66. [PubMed] [Google Scholar]
  18. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Poynard T., Opolon P. Hepatitis C: somber views of natural history and optimistic views of interferon treatment? Hepatology. 1998 May;27(5):1443–1444. doi: 10.1002/hep.510270537. [DOI] [PubMed] [Google Scholar]
  20. Serfaty L., Aumaître H., Chazouillères O., Bonnand A. M., Rosmorduc O., Poupon R. E., Poupon R. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology. 1998 May;27(5):1435–1440. doi: 10.1002/hep.510270535. [DOI] [PubMed] [Google Scholar]
  21. Tsukuma H., Hiyama T., Tanaka S., Nakao M., Yabuuchi T., Kitamura T., Nakanishi K., Fujimoto I., Inoue A., Yamazaki H. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med. 1993 Jun 24;328(25):1797–1801. doi: 10.1056/NEJM199306243282501. [DOI] [PubMed] [Google Scholar]
  22. Valla D. C., Chevallier M., Marcellin P., Payen J. L., Trepo C., Fonck M., Bourliere M., Boucher E., Miguet J. P., Parlier D. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology. 1999 Jun;29(6):1870–1875. doi: 10.1002/hep.510290616. [DOI] [PubMed] [Google Scholar]
  23. Yoshida H., Shiratori Y., Moriyama M., Arakawa Y., Ide T., Sata M., Inoue O., Yano M., Tanaka M., Fujiyama S. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med. 1999 Aug 3;131(3):174–181. doi: 10.7326/0003-4819-131-3-199908030-00003. [DOI] [PubMed] [Google Scholar]
  24. Zoli M., Magalotti D., Bianchi G., Gueli C., Marchesini G., Pisi E. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer. 1996 Sep 1;78(5):977–985. doi: 10.1002/(SICI)1097-0142(19960901)78:5<977::AID-CNCR6>3.0.CO;2-9. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES